{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Subjects who relapsed during the Follow-Up Period of HZNP-TEP-301 and choose to enter this', 'extension study will not participate in the Follow-Up Period. For these subjects, the last clinic', 'visit is at Week 24. Those who complete the Week 24 Visit will be contacted 6 and 12 months', 'later via phone or email by research staff to enquire if any treatment for TED has been received', 'since last study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', 'An overview of the study design is presented in Figure 9.1, and details of study activities were', 'previously presented in Section 2.1, Schedule of Assessments.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 70 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Figure 9.1', 'Schematic of Study Design', 'Subjects who were proptosis non-responders in Study HZNP-TEP-301', 'Teprotumumab Open-Label Treatment Period\u00b9', 'Follow-Up Period', 'Follow-Up Contact4', '24 Weeks\u00b2', '24 Weeks\u00b3', '48 Weeks', 'Clinic Visits', 'Day 15,6', 'W1', 'W36', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W247', 'W28', 'W36', 'W488', 'W72', 'W96', 'Baseline', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M18', 'M24', 'Study Week/Month', 'Subjects who relapsed in Study HZNP-TEP-301', 'Teprotumumab Open-Label Treatment Period\u00b9', 'Follow-Up Contact4', '24 Weeks\u00b2', '48 Weeks', 'Clinic Visits', 'Day 15,6', 'W1', 'W36', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W247', 'W48', 'W72', 'Baseline', 'M1', 'M3', 'M6', 'M12', 'M18', 'Study Week/Month', '* Infusion of study drug. M=Month; W=Week.', '1.', 'Teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions).', '2.', 'Visit windows are 1 day for Weeks 1 and 4, 3 days for Weeks 3, 6, 9, 12, 15, 18, and 21, and 7 days for Week 24.', '3.', 'Visit windows of 7 days.', '4.', 'Proptosis non-responders from Study HZNP-TEP-301 who complete the Month 12 Visit and subjects who relapsed during the Follow-Up', 'Period of HZNP-TEP-301 and complete the Week 24 Visit.', '5.', 'Visit must occur within 14 days after the final visit of HZNP-TEP-301.', '6.', 'Subjects will be contacted by phone/email the day following the first and second infusions for safety and tolerability assessments;', 'phone/email contacts will also occur the day after any clinic visit where a subject experiences an infusion-related AE.', '7.', 'If a subject wishes to discontinue dosing, the subject will return to the clinic and undergo the scheduled Week 24 assessments.', '8.', 'If a subject participates in the Follow-Up Period and prematurely discontinues prior to Month 12, he/she will return to the clinic and', 'undergo the Month 12 assessments prior to study discharge.', '9.2', 'Discussion of Study Design', 'The study population consists of subjects who participated in the lead-in study (HZNP-TEP-301)', 'and who were either proptosis non-responders at Week 24 of HZNP-TEP-301 or were proptosis', 'responders at Week 24 but meet the criteria for re-treatment due to relapse (see Section 9.3.4)', 'during the Follow-Up Period of HZNP-TEP-301. The study population enrolled in HZNP-TEP-', '301 was well-defined and consistent with the expected target population for whom', 'teprotumumab will be indicated (adult subjects with active moderate-to-severe TED).', 'The measurements used in this study for the primary and secondary endpoints (proptosis, CAS,', 'and GO-QoL questionnaire) are established and well-validated endpoints that have been shown', 'to correlate significantly with TED.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 71 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'In order to maintain the study mask in HZNP-TEP-301, all subjects in this open-label extension', 'study will undergo the same dosing regimen of teprotumumab (10 mg/kg on Day 1 followed by', '20 mg/kg q3W for the remaining 7 infusions), regardless if they received teprotumumab or', 'placebo in HZNP-TEP-301.', 'Given the teratogenic effects of teprotumumab noted in a monkey embryo-fetal development', 'toxicity study (see Section 7.1.3.2 for details) and PK profile of teprotumumab (see', 'Section 7.1.3.4.3), all subjects (men and women) are required to use adequate contraception and', 'report any pregnancies for at least 6 months after the last dose of study drug. Six months after the', 'last dose, the estimated plasma concentration (0.2 g/mL) is considered reasonably safe with a', 'low risk of teratogenicity. Furthermore, a 6-month waiting period is in line with', 'recommendations given for other teratogens, such as cytostatic chemotherapy.', '9.3', 'Selection of Study Population', '9.3.1', 'Inclusion Criteria', 'Eligible subjects must meet all of the following criteria:', '1. Written informed consent.', '2. Completed the 24-week double-masked Treatment Period in Study HZNP-TEP-301.', '3. Proptosis non-responder (<2 mm reduction in proptosis in the study eye) at Week 24 of', 'Study HZNP-TEP-301 OR proptosis responder at Week 24 who relapses (see', 'Section 9.3.4) during the Follow-Up Period of Study HZNP-TEP-301.', '4. Subject must be euthyroid with the baseline disease under control, or have mild hypo- or', 'hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine [FT3] levels', '< 50% above or below the normal limits) at the most recent clinic visit. Every effort', 'should be made to correct the mild hypo- or hyperthyroidism promptly and to maintain', 'the euthyroid state for the full duration of the clinical trial.', '5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <3 times the upper', 'limit of normal (ULN) or serum creatinine <1.5 times the ULN (according to age) at the', 'most recent clinic visit.', '6. Diabetic subjects must have well-controlled disease (defined as HbAlc < 9.0% at most', 'recent clinic visit).', '7. Does not require immediate surgical ophthalmological intervention and is not planning', 'corrective surgery/irradiation during the course of the study.', '8. Women of childbearing potential must have a negative urine pregnancy test at', 'Baseline/Day 1. Subjects who are sexually active with a non-vasectomized male partner', 'must agree to use 2 reliable forms of contraception during the trial and continue for', '180 days after the last dose of study drug. One of the 2 forms of contraception is', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 72 of 118']\n\n###\n\n", "completion": "END"}